Article
<i>De novo</i> design of anti-variant COVID-19 Vaccine
2022-10-20
Abstract excerpt
Recent studies have shown the efficacy of hybrid SARS-COV-2 vaccines using wild-type nucleocapsid (N) and Spike (S) protein. We upgraded this strategy one step further using clinically proven spike protein by considering the delta and post-delta omicron variant of concern (VOC) mutations and nucleocapsid peptides conferring T-cell immunity. Nucleocapsid peptides are considered much better immunological replacement...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4d0ca71d-243b-5047-bfb7-ebc0afc1a2d5
- DOI
- 10.1101/2022.10.20.513049
